Related Experiment Video

Updated: Jun 24, 2026

Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

Promises of co-stimulatory inhibition for durable and repeatable AAV gene therapy

Klaudia Kuranda1, David Alexandre Gross2, Giuseppe Ronzitti2

  • 1Genethon, 91000 Evry, France.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|June 22, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

Related Experiment Videos

Last Updated: Jun 24, 2026

Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Articles linked to this work by shared authors, journal, and citation graph.

Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model.

Acta neuropathologica communications·2026

Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.

Molecular therapy. Advances·2026

CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity.

JCI insight·2026

Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses.

Frontiers in immunology·2026

CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Interindividual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoring.

JCI insight·2026

Protein-based masks to unlock conditional activation of therapeutics.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Optimization of AsCas12f1-Mediated Long-Term Gene Repression.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Ammonium tetrathiomolybdate improves auditory and vestibular function after gentamicin exposure via the NRF2-GPX4 axis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

BRD4 Inhibition Mitigates Acute and Chronic Corneal Injury Following Topical Nitrogen Mustard Exposure.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

AAV-mediated CBLN1 replacement rescues hereditary ataxia caused by biallelic CBLN1 variants.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Inhaled nanosilica orchestrates a pulmonary macrophage-NK cell axis for memory-like NK programming toward synergistic cancer immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Chimpanzees attribute agency to virtual animals, but not to self-propelled shapes.

Proceedings. Biological sciences·2026

Neural integrator and orchestrator communities shape spontaneous signaling in the human brain.

PNAS nexus·2026

VLM-guided retrieval augmented generation (RAG) for robot action prediction.

Frontiers in neurorobotics·2026

An automated method for constructing continuous reference intervals based on real-world data-driven approaches and forming intelligent agents.

Clinical biochemistry·2026

Integration of Patient-Based Real-Time Quality Control with Conventional Internal Quality Control: Improved Error Detection and Cost-Benefit Analysis in a Clinical Laboratory.

EJIFCC·2026

A Process-Driven Low-Voltage Acceptance Automation Platform with Visual Workflow Orchestration and Machine Learning Validation.

Journal of visualized experiments : JoVE·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us